On October 25, 2024, Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics announced that it had priced an underwritten offering of 3,642,988 American Depositary Shares (ADSs) representing 3,642,988 new shares at an offering price of USD 5.49 per ADS amounting to gross proceeds of USD 20 m. The offering included participation from a new investor HBM Healthcare Investments Ltd, which is a leading healthcare investor, as well as multiple existing investors.

Molecular Partners currently intends to use the net proceeds from this offering for the development and expansion of its radiopharmaceutical pipeline and platform (Radio-DARPin Therapeutics) and other general corporate purposes.

The Homburger team was led by Dieter Gericke and Karin Mattle (both Corporate / M&A, Capital Markets) and included Stefan Oesterhelt (Tax), Lorenzo Togni, Romain Fakhoury and Hans Glent Abildgaard (all Corporate / M&A, Capital Markets).